Here's What UBS Thinks About Eli Lilly and Company (LLY)

Eli Lilly and Company (NYSE:LLY) is one of the Best Unstoppable Growth Stocks to Buy Right Now. On January 7, Michael Yee from UBS initiated coverage of Eli Lilly and Company (NYSE:LLY) with a Buy rating and raised the price target from $1,080 to $1,250. The analyst noted the company’s leadership in the obesity treatment market as one of the key factors behind his bullish sentiment.

The firm highlighted that the company’s performance in 2026 would be driven by the anticipated approval of obesity drug Orfo. The approval of the drug seems imminent as Eli Lilly and Company (NYSE:LLY) filed for regulatory approval in early December. The firm also believes that the approval could lead the company to exceed Wall Street’s consensus estimates for 2026-2028. Moreover, UBS also cited that Medicare coverage for obesity treatments is expected to begin in 2026. This coverage is anticipated to help the company boost adoption of its approved and upcoming obesity treatments.

That said, earlier on January 5, Leerink Partners also raised the price target on the stock from $1,104 to $1,234 and maintained a Buy rating. Leerink Partners also cited the upcoming launch of Orfo as one of the tailwinds boosting the company’s long-term potential.

Eli Lilly and Company (NYSE:LLY) operates as a global pharmaceutical firm focused on discovering, developing, manufacturing, and marketing medicines for major health challenges.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.